Immunoprotein Diagnostic Testing Market by Technology (Radioimmunoassay, Immunoturbidity Assay, Immunoprotein Electrophoresis, Enzyme-linked Immunosorbent assay and Others), Type (C-reactive Protein Diagnostic Test, Complement System Protein Diagnostic Test, Pre-albumin Diagnostic Test, Haptoglobin Diagnostic Test, Immunoglobulin Diagnostic Test, and Free Light Chain Diagnostic Test and Others), and Application (Autoimmune Disease Testing, Infectious Disease Testing, Allergy Testing, Endocrine Testing, Oncology Testing, and Toxicology Testing): Global Opportunity Analysis and Industry Forecast, 2020–2027
The global immunoprotein diagnostic testing market was valued at $10,136.40 million in 2019 and is projected to reach $18,387.19 million by 2027, registering a CAGR of 6.6% from 2020 to 2027. Immunoprotein is an immunologically active protein, which provides immunity against pathogenic organisms or substances. These proteins form the integrated body system of tissues, organs, cells, or cell products that neutralize antigens. They enable the diagnosis of various diseases, such as cardiovascular, oncology, infectious diseases, and others, as they display an abnormal increase in their concentration when in a diseased state.
The growth of the global immunoprotein diagnostic testing market is propelled by increase in incidence & prevalence of infectious and chronic diseases, rise in geriatric population, and growth in demand for early diagnostic services. In addition, technological advancements in immunodiagnostic instruments and introduction of novel automated systems are all set to augment the growth of immunoprotein diagnostic testing market during the forecast period. On the contrary, complex regulatory framework for immunoprotein diagnostic testing limits the growth of the market. Conversely, ongoing development in condition-specific assays & tests and the need for early diagnosis in the emerging economies across the world provide lucrative opportunities for the market growth.
The immunoprotein diagnostic testing market is segmented on the basis of type, application, technology, and region. Based on technology, the immunoprotein diagnostic testing market is classified into radioimmunoassay, immunoturbidity assay, immunoprotein electrophoresis, enzyme-linked immunosorbent assay, and others. Under the enzyme-linked immunosorbent assay, the market is further divided into chemiluminescence immunoassay, fluorescence immunoassay, and colorimetric immunoassay. Based on type, the market is categorized into C-reactive protein diagnostic test, complement system protein diagnostic test, pre-albumin diagnostic test, haptoglobin diagnostic test, immunoglobulin diagnostic test, free light chain diagnostic test, and others. Applications of immunoprotein diagnostic testing covered in the study include autoimmune disease testing, infectious disease testing, allergy testing, endocrine testing, oncology testing, toxicology testing, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
The growth of the global immunoprotein diagnostic testing market is propelled by increase in incidence & prevalence of infectious and chronic diseases, rise in geriatric population, and growth in demand for early diagnostic services. In addition, technological advancements in immunodiagnostic instruments and introduction of novel automated systems are all set to augment the growth of immunoprotein diagnostic testing market during the forecast period. On the contrary, complex regulatory framework for immunoprotein diagnostic testing limits the growth of the market. Conversely, ongoing development in condition-specific assays & tests and the need for early diagnosis in the emerging economies across the world provide lucrative opportunities for the market growth.
The immunoprotein diagnostic testing market is segmented on the basis of type, application, technology, and region. Based on technology, the immunoprotein diagnostic testing market is classified into radioimmunoassay, immunoturbidity assay, immunoprotein electrophoresis, enzyme-linked immunosorbent assay, and others. Under the enzyme-linked immunosorbent assay, the market is further divided into chemiluminescence immunoassay, fluorescence immunoassay, and colorimetric immunoassay. Based on type, the market is categorized into C-reactive protein diagnostic test, complement system protein diagnostic test, pre-albumin diagnostic test, haptoglobin diagnostic test, immunoglobulin diagnostic test, free light chain diagnostic test, and others. Applications of immunoprotein diagnostic testing covered in the study include autoimmune disease testing, infectious disease testing, allergy testing, endocrine testing, oncology testing, toxicology testing, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2027, which assists to identify the prevailing market opportunities.
- An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the global immunoprotein diagnostic testing market is provided.
- An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
- By Product Type
- C-reactive Protein Diagnostic Test
- Complement System Protein Diagnostic Test
- Pre-albumin Diagnostic Test
- Haptoglobin Diagnostic Test
- Immunoglobulin Diagnostic Test
- Free Light Chain Diagnostic Test
- Others
- By Application
- Autoimmune Testing
- Infectious Disease Testing
- Allergy Testing
- Endocrine Testing
- Oncology Testing
- Toxicology Testing
- Others
- By Technology
- Radioimmunoassay
- Immunoturbidity Assay
- Immunoprotein Electrophoresis
- Enzyme-linked immunosorbent assay
- Chemiluminescence Immunoassay
- Fluorescence Immunoassay
- Colorimetric immunoassay
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Australia
- Japan
- India
- China
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Rest of LAMEA
- Abbott Laboratories
- Abcam PLC
- Bio-Rad Laboratories
- Danaher Corporation
- Diasorin
- Enzo Life Sciences
- Ortho Clinical Diagnostics
- Roche Diagnostics
- Siemens Healthcare
- Thermo Fisher Scientific
CHAPTER 1:INTRODUCTION
1.1.Report description
1.1.Key benefits for stakeholders
1.2.Key market segments
1.3.Research Methodology
1.3.1.Secondary research
1.3.2.Primary research
1.3.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market Definition and Scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s Five Forces Analysis
3.4.Market Dynamics
3.4.1.Drivers
3.4.1.1.Increasing incidence of chronic and infectious diseases
3.4.1.2.Technological advancements
3.4.2.Restraint
3.4.2.1.Stringent Regulations
3.4.3.Opportunities
3.4.3.1.Lucrative opportunities from emerging economies
3.4.3.2.Development of condition-specific assays and tests
3.5.COVID-19 Impact Analysis on Market
CHAPTER 4:IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY
4.1.Overview
4.1.1.Market size and forecast
4.2.Radioimmunoassay (RIA)
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Immunoturbidity assay
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Immunoprotein Electrophoresis
4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
4.5.Enzyme Based Immunoassay
4.5.1.Key market trends and opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country
4.5.3.1.Chemiluminescence Immunoassay (CLIA)
4.5.3.2.Immunofluorescence Assay
4.5.3.3.Colorimetric Immunoassay (CI)
4.6.Others
4.6.1.Key market trends and opportunities
4.6.2.Market size and forecast
4.6.3.Market analysis, by country
CHAPTER 5:IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE
5.1.Overview
5.1.1.Market size and forecast, by type
5.2.C-reactive protein diagnostic tests
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Complement system protein diagnostic tests
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
5.4.Pre-albumin diagnostic tests
5.4.1.Market size and forecast
5.4.2.Market analysis, by country
5.5.Haptoglobin diagnostic tests
5.5.1.Market size and forecast
5.5.2.Market analysis, by country
5.6.Immunoglobulin diagnostic tests
5.6.1.Market size and forecast
5.6.2.Market analysis, by country
5.7.Free light chain diagnostic tests
5.7.1.Market size and forecast
5.7.2.Market analysis, by country
5.8.Others
5.8.1.Market size and forecast
5.8.2.Market analysis, by country
CHAPTER 6:IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION
6.1.Overview
6.1.1.Market size and forecast
6.2.Autoimmune Testing
6.2.1.Market size and forecast
6.2.2.Market analysis, by country
6.3.Infectious Disease Testing
6.3.1.Market size and forecast
6.3.2.Market analysis, by country
6.4.Allergy Testing
6.4.1.Market size and forecast
6.4.2.Market analysis, by country
6.5.Endocrine Testing
6.5.1.Market size and forecast
6.5.2.Market analysis, by country
6.6.Oncology Testing
6.6.1.Market size and forecast
6.6.2.Market analysis, by country
6.7.Toxicology Testing
6.7.1.Market size and forecast
6.7.2.Market analysis, by country
6.8.Others
6.8.1.Market size and forecast
6.8.2.Market analysis, by country
CHAPTER 7:IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by country
7.2.3.Market size and forecast, by technology
7.2.4.Market size and forecast, by type
7.2.5.Market size and forecast, by application
7.2.6.U.S.
7.2.6.1.U.S. market size and forecast, by technology
7.2.6.2.U.S. market size and forecast, by type
7.2.6.3.U.S. market size and forecast, by application
7.2.7.Canada
7.2.7.1.Canada market size and forecast, by technology
7.2.7.2.Canada market size and forecast, by type
7.2.7.3.Canada market size and forecast, by application
7.2.8.Mexico
7.2.8.1.Mexico market size and forecast, by technology
7.2.8.2.Mexico market size and forecast, by type
7.2.8.3.Mexico market size and forecast, by application
7.3.Europe
7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast, by country
7.3.3.Market size and forecast, by technology
7.3.4.Market size and forecast, by type
7.3.5.Market size and forecast, by application
7.3.6.Germany
7.3.6.1.Germany market size and forecast, by technology
7.3.6.2.Germany market size and forecast, by type
7.3.6.3.Germany market size and forecast, by application
7.3.7.France
7.3.7.1.France market size and forecast, by technology
7.3.7.2.France market size and forecast, by type
7.3.7.3.France market size and forecast, by application
7.3.8.UK
7.3.8.1.UK market size and forecast, by technology
7.3.8.2.UK market size and forecast, by type
7.3.8.3.UK market size and forecast, by application
7.3.9.Italy
7.3.9.1.Italy market size and forecast, by technology
7.3.9.2.Italy market size and forecast, by type
7.3.9.3.Italy market size and forecast, by application
7.3.10.Spain
7.3.10.1.Spain market size and forecast, by technology
7.3.10.2.Spain market size and forecast, by type
7.3.10.3.Spain market size and forecast, by application
7.3.11.Rest of Europe
7.3.11.1.Rest of Europe market size and forecast, by technology
7.3.11.2.Rest of Europe market size and forecast, by type
7.3.11.3.Rest of Europe market size and forecast, by application
7.4.Asia-Pacific
7.4.1.Key market trends and opportunities
7.4.2.Market size and forecast, by country
7.4.3.Market size and forecast, by technology
7.4.4.Market size and forecast, by type
7.4.5.Market size and forecast, by application
7.4.6.Japan
7.4.6.1.Japan market size and forecast, by technology
7.4.6.2.Japan market size and forecast, by type
7.4.6.3.Japan market size and forecast, by application
7.4.7.China
7.4.7.1.China market size and forecast, by technology
7.4.7.2.China market size and forecast, by type
7.4.7.3.China market size and forecast, by application
7.4.8.India
7.4.8.1.India market size and forecast, by technology
7.4.8.2.India market size and forecast, by type
7.4.8.3.India market size and forecast, by application
7.4.9.Rest of Asia-Pacific
7.4.9.1.Rest of Asia-Pacific market size and forecast, by technology
7.4.9.2.Rest of Asia-Pacific market size and forecast, by type
7.4.9.3.Rest of Asia-Pacific market size and forecast, by application
7.5.LAMEA
7.5.1.Key market trends and opportunities
7.5.2.Market size and forecast, by country
7.5.3.Market size and forecast, by technology
7.5.4.Market size and forecast, by type
7.5.5.Market size and forecast, by application
7.5.6.Brazil
7.5.6.1.Brazil market size and forecast, by technology
7.5.6.2.Brazil market size and forecast, by type
7.5.6.3.Brazil market size and forecast, by application
7.5.7.South Africa
7.5.7.1.South Africa market size and forecast, by technology
7.5.7.2.South Africa market size and forecast, by type
7.5.7.3.South Africa market size and forecast, by application
7.5.8.Rest of LAMEA
7.5.8.1.Rest of LAMEA market size and forecast, by technology
7.5.8.2.Rest of LAMEA market size and forecast, by type
7.5.8.3.Rest of LAMEA market size and forecast, by application
CHAPTER 8:COMPANY PROFILES
8.1.Abbott Laboratories
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.Abcam plc.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product Portfolio
8.2.5.Business performance
8.3.Bio-Rad Laboratories, Inc.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.Danaher Corporation
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.5.Diasorin S.P.A
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.Enzo Biochem, Inc.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.F. Hoffmann-La Roche AG (Roche Diagnostics)
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.Ortho Clinical Diagnostics
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Key strategic moves and developments
8.9.Siemens AG
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.Thermo Fisher Scientific Inc.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
1.1.Report description
1.1.Key benefits for stakeholders
1.2.Key market segments
1.3.Research Methodology
1.3.1.Secondary research
1.3.2.Primary research
1.3.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market Definition and Scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s Five Forces Analysis
3.4.Market Dynamics
3.4.1.Drivers
3.4.1.1.Increasing incidence of chronic and infectious diseases
3.4.1.2.Technological advancements
3.4.2.Restraint
3.4.2.1.Stringent Regulations
3.4.3.Opportunities
3.4.3.1.Lucrative opportunities from emerging economies
3.4.3.2.Development of condition-specific assays and tests
3.5.COVID-19 Impact Analysis on Market
CHAPTER 4:IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY
4.1.Overview
4.1.1.Market size and forecast
4.2.Radioimmunoassay (RIA)
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Immunoturbidity assay
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Immunoprotein Electrophoresis
4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
4.5.Enzyme Based Immunoassay
4.5.1.Key market trends and opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country
4.5.3.1.Chemiluminescence Immunoassay (CLIA)
4.5.3.2.Immunofluorescence Assay
4.5.3.3.Colorimetric Immunoassay (CI)
4.6.Others
4.6.1.Key market trends and opportunities
4.6.2.Market size and forecast
4.6.3.Market analysis, by country
CHAPTER 5:IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE
5.1.Overview
5.1.1.Market size and forecast, by type
5.2.C-reactive protein diagnostic tests
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Complement system protein diagnostic tests
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
5.4.Pre-albumin diagnostic tests
5.4.1.Market size and forecast
5.4.2.Market analysis, by country
5.5.Haptoglobin diagnostic tests
5.5.1.Market size and forecast
5.5.2.Market analysis, by country
5.6.Immunoglobulin diagnostic tests
5.6.1.Market size and forecast
5.6.2.Market analysis, by country
5.7.Free light chain diagnostic tests
5.7.1.Market size and forecast
5.7.2.Market analysis, by country
5.8.Others
5.8.1.Market size and forecast
5.8.2.Market analysis, by country
CHAPTER 6:IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION
6.1.Overview
6.1.1.Market size and forecast
6.2.Autoimmune Testing
6.2.1.Market size and forecast
6.2.2.Market analysis, by country
6.3.Infectious Disease Testing
6.3.1.Market size and forecast
6.3.2.Market analysis, by country
6.4.Allergy Testing
6.4.1.Market size and forecast
6.4.2.Market analysis, by country
6.5.Endocrine Testing
6.5.1.Market size and forecast
6.5.2.Market analysis, by country
6.6.Oncology Testing
6.6.1.Market size and forecast
6.6.2.Market analysis, by country
6.7.Toxicology Testing
6.7.1.Market size and forecast
6.7.2.Market analysis, by country
6.8.Others
6.8.1.Market size and forecast
6.8.2.Market analysis, by country
CHAPTER 7:IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by country
7.2.3.Market size and forecast, by technology
7.2.4.Market size and forecast, by type
7.2.5.Market size and forecast, by application
7.2.6.U.S.
7.2.6.1.U.S. market size and forecast, by technology
7.2.6.2.U.S. market size and forecast, by type
7.2.6.3.U.S. market size and forecast, by application
7.2.7.Canada
7.2.7.1.Canada market size and forecast, by technology
7.2.7.2.Canada market size and forecast, by type
7.2.7.3.Canada market size and forecast, by application
7.2.8.Mexico
7.2.8.1.Mexico market size and forecast, by technology
7.2.8.2.Mexico market size and forecast, by type
7.2.8.3.Mexico market size and forecast, by application
7.3.Europe
7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast, by country
7.3.3.Market size and forecast, by technology
7.3.4.Market size and forecast, by type
7.3.5.Market size and forecast, by application
7.3.6.Germany
7.3.6.1.Germany market size and forecast, by technology
7.3.6.2.Germany market size and forecast, by type
7.3.6.3.Germany market size and forecast, by application
7.3.7.France
7.3.7.1.France market size and forecast, by technology
7.3.7.2.France market size and forecast, by type
7.3.7.3.France market size and forecast, by application
7.3.8.UK
7.3.8.1.UK market size and forecast, by technology
7.3.8.2.UK market size and forecast, by type
7.3.8.3.UK market size and forecast, by application
7.3.9.Italy
7.3.9.1.Italy market size and forecast, by technology
7.3.9.2.Italy market size and forecast, by type
7.3.9.3.Italy market size and forecast, by application
7.3.10.Spain
7.3.10.1.Spain market size and forecast, by technology
7.3.10.2.Spain market size and forecast, by type
7.3.10.3.Spain market size and forecast, by application
7.3.11.Rest of Europe
7.3.11.1.Rest of Europe market size and forecast, by technology
7.3.11.2.Rest of Europe market size and forecast, by type
7.3.11.3.Rest of Europe market size and forecast, by application
7.4.Asia-Pacific
7.4.1.Key market trends and opportunities
7.4.2.Market size and forecast, by country
7.4.3.Market size and forecast, by technology
7.4.4.Market size and forecast, by type
7.4.5.Market size and forecast, by application
7.4.6.Japan
7.4.6.1.Japan market size and forecast, by technology
7.4.6.2.Japan market size and forecast, by type
7.4.6.3.Japan market size and forecast, by application
7.4.7.China
7.4.7.1.China market size and forecast, by technology
7.4.7.2.China market size and forecast, by type
7.4.7.3.China market size and forecast, by application
7.4.8.India
7.4.8.1.India market size and forecast, by technology
7.4.8.2.India market size and forecast, by type
7.4.8.3.India market size and forecast, by application
7.4.9.Rest of Asia-Pacific
7.4.9.1.Rest of Asia-Pacific market size and forecast, by technology
7.4.9.2.Rest of Asia-Pacific market size and forecast, by type
7.4.9.3.Rest of Asia-Pacific market size and forecast, by application
7.5.LAMEA
7.5.1.Key market trends and opportunities
7.5.2.Market size and forecast, by country
7.5.3.Market size and forecast, by technology
7.5.4.Market size and forecast, by type
7.5.5.Market size and forecast, by application
7.5.6.Brazil
7.5.6.1.Brazil market size and forecast, by technology
7.5.6.2.Brazil market size and forecast, by type
7.5.6.3.Brazil market size and forecast, by application
7.5.7.South Africa
7.5.7.1.South Africa market size and forecast, by technology
7.5.7.2.South Africa market size and forecast, by type
7.5.7.3.South Africa market size and forecast, by application
7.5.8.Rest of LAMEA
7.5.8.1.Rest of LAMEA market size and forecast, by technology
7.5.8.2.Rest of LAMEA market size and forecast, by type
7.5.8.3.Rest of LAMEA market size and forecast, by application
CHAPTER 8:COMPANY PROFILES
8.1.Abbott Laboratories
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.Abcam plc.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product Portfolio
8.2.5.Business performance
8.3.Bio-Rad Laboratories, Inc.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.Danaher Corporation
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.5.Diasorin S.P.A
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.Enzo Biochem, Inc.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.F. Hoffmann-La Roche AG (Roche Diagnostics)
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.Ortho Clinical Diagnostics
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Key strategic moves and developments
8.9.Siemens AG
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.Thermo Fisher Scientific Inc.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
LIST OF TABLES
TABLE 01.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 02.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR RADIOIMMUNOASSAY (RIA), BY REGION, 2019–2027 ($MILLION)
TABLE 03.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR IMMUNOTURBIDITY ASSAYS, BY REGION, 2019–2027 ($MILLION)
TABLE 04.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR IMMUNOPROTEIN ELECTROPHORESIS, BY REGION, 2019–2027 ($MILLION)
TABLE 05.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2019–2027 ($MILLION)
TABLE 06.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 07.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2019 - 2027 ($MILLION)
TABLE 08.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR C-REACTIVE PROTEIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 09.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR COMPLEMENT SYSTEM PROTEIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 10.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR PRE-ALBUMIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 11.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR HAPTOGLOBIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 12.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR IMMUNOGLOBULIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 13.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR FREE LIGHT CHAIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 14.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR OTHERS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 15.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 16.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR AUTOIMMUNE TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 17.INFECTIOUS DISEASES CAUSED BY BACTERIA, VIRUS AND PARASITES
TABLE 18.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 19.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ALLERGY TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 20.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ENDOCRINE TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 21.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ONCOLOGY TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 22.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR TOXICOLOGY TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 23.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 24.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 25.NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 26.NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 27.NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 28.NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 29.U.S. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 30.U.S. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 31.U.S IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 32.CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 33.CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 34.CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 35.MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 36.MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 37.MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 38.EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 39.EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 40.EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 41.EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 42.GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 43.GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 44.GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 45.FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 46.FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 47.FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 48.UK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 49.UK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 50.UK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 51.ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 52.ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 53.ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 54.SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 55.SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 56.SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 57.REST OF EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 58.REST OF EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 59.REST OF EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 60.ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 61.ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 62.ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 63.ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 64.JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 65.JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 66.JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 67.CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 68.CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 69.CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 70.INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 71.INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 72.INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 74.REST OF ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 76.ESTIMATED NUMBER OF NEW CANCER CASES, 2018
TABLE 77.SOUTH AFRICA TOP 10 CAUSES OF DEATH (2017)
TABLE 78.LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 79.LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 80.LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 81.LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 82.BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 83.BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 84.BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 85.SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 86.SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 87.SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 88.REST OF LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 89.REST OF LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 90.REST OF LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 91.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 92.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 93.ABBOTT LABORATORIES PLC: PRODUCT PORTFOLIO
TABLE 94.ABCAM: COMPANY SNAPSHOT
TABLE 95.ABCAM: BUSINESS UNITS
TABLE 96.ABCAM: PRODUCT PORTFOLIO
TABLE 97.BIO-RAD: COMPANY SNAPSHOT
TABLE 98.BIO-RAD: PRODUCT SEGMENTS
TABLE 99.BIO-RAD: PRODUCT PORTFOLIO
TABLE 100.DANAHER: COMPANY SNAPSHOT
TABLE 101.DANAHER: OPERATING SEGMENTS
TABLE 102.DANAHER: PRODUCT PORTFOLIO
TABLE 103.DIASORIN: COMPANY SNAPSHOT
TABLE 104.DIASORIN: PRODUCT SEGMENTS
TABLE 105.DIASORIN: PRODUCT PORTFOLIO
TABLE 106.ENZO: COMPANY SNAPSHOT
TABLE 107.ENZO: OPERATING SEGMENTS
TABLE 108.ENZO: PRODUCT PORTFOLIO
TABLE 109.ROCHE: COMPANY SNAPSHOT
TABLE 110.ROCHE: OPERATING BUSINESS SEGMENTS
TABLE 111.ROCHE: PRODUCT PORTFOLIO
TABLE 112.ORTHO: COMPANY SNAPSHOT
TABLE 113.ORTHO: OPERATING BUSINESS SEGMENTS
TABLE 114.ORTHO: PRODUCT PORTFOLIO
TABLE 115.SIEMENS: COMPANY SNAPSHOT
TABLE 116.SIEMENS: OPERATING BUSINESS SEGMENTS
TABLE 117.SIEMENS: PRODUCT PORTFOLIO
TABLE 118.THERMO FISHER: COMPANY SNAPSHOT
TABLE 119.THERMO FISHER: OPERATING SEGMENTS
TABLE 120.THERMO FISHER: PRODUCT PORTFOLIO
TABLE 01.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 02.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR RADIOIMMUNOASSAY (RIA), BY REGION, 2019–2027 ($MILLION)
TABLE 03.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR IMMUNOTURBIDITY ASSAYS, BY REGION, 2019–2027 ($MILLION)
TABLE 04.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR IMMUNOPROTEIN ELECTROPHORESIS, BY REGION, 2019–2027 ($MILLION)
TABLE 05.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2019–2027 ($MILLION)
TABLE 06.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 07.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2019 - 2027 ($MILLION)
TABLE 08.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR C-REACTIVE PROTEIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 09.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR COMPLEMENT SYSTEM PROTEIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 10.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR PRE-ALBUMIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 11.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR HAPTOGLOBIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 12.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR IMMUNOGLOBULIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 13.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR FREE LIGHT CHAIN DIAGNOSTIC TESTS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 14.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR OTHERS, BY REGION, 2019 - 2027 ($MILLION)
TABLE 15.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 16.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR AUTOIMMUNE TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 17.INFECTIOUS DISEASES CAUSED BY BACTERIA, VIRUS AND PARASITES
TABLE 18.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 19.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ALLERGY TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 20.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ENDOCRINE TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 21.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ONCOLOGY TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 22.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR TOXICOLOGY TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 23.IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 24.IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 25.NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 26.NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 27.NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 28.NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 29.U.S. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 30.U.S. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 31.U.S IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 32.CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 33.CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 34.CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 35.MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 36.MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 37.MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 38.EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 39.EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 40.EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 41.EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 42.GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 43.GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 44.GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 45.FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 46.FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 47.FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 48.UK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 49.UK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 50.UK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 51.ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 52.ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 53.ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 54.SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 55.SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 56.SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 57.REST OF EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 58.REST OF EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 59.REST OF EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 60.ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 61.ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 62.ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 63.ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 64.JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 65.JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 66.JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 67.CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 68.CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 69.CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 70.INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 71.INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 72.INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 74.REST OF ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 76.ESTIMATED NUMBER OF NEW CANCER CASES, 2018
TABLE 77.SOUTH AFRICA TOP 10 CAUSES OF DEATH (2017)
TABLE 78.LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 79.LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 80.LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2019-2027 ($MILLION)
TABLE 81.LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 82.BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 83.BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 84.BRAZIL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 85.SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 86.SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 87.SOUTH AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 88.REST OF LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TECHNOLOGY, 2019-2027 ($MILLION)
TABLE 89.REST OF LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY TYPE, 2019-2027 ($MILLION)
TABLE 90.REST OF LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET BY APPLICATION, 2019-2027 ($MILLION)
TABLE 91.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 92.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 93.ABBOTT LABORATORIES PLC: PRODUCT PORTFOLIO
TABLE 94.ABCAM: COMPANY SNAPSHOT
TABLE 95.ABCAM: BUSINESS UNITS
TABLE 96.ABCAM: PRODUCT PORTFOLIO
TABLE 97.BIO-RAD: COMPANY SNAPSHOT
TABLE 98.BIO-RAD: PRODUCT SEGMENTS
TABLE 99.BIO-RAD: PRODUCT PORTFOLIO
TABLE 100.DANAHER: COMPANY SNAPSHOT
TABLE 101.DANAHER: OPERATING SEGMENTS
TABLE 102.DANAHER: PRODUCT PORTFOLIO
TABLE 103.DIASORIN: COMPANY SNAPSHOT
TABLE 104.DIASORIN: PRODUCT SEGMENTS
TABLE 105.DIASORIN: PRODUCT PORTFOLIO
TABLE 106.ENZO: COMPANY SNAPSHOT
TABLE 107.ENZO: OPERATING SEGMENTS
TABLE 108.ENZO: PRODUCT PORTFOLIO
TABLE 109.ROCHE: COMPANY SNAPSHOT
TABLE 110.ROCHE: OPERATING BUSINESS SEGMENTS
TABLE 111.ROCHE: PRODUCT PORTFOLIO
TABLE 112.ORTHO: COMPANY SNAPSHOT
TABLE 113.ORTHO: OPERATING BUSINESS SEGMENTS
TABLE 114.ORTHO: PRODUCT PORTFOLIO
TABLE 115.SIEMENS: COMPANY SNAPSHOT
TABLE 116.SIEMENS: OPERATING BUSINESS SEGMENTS
TABLE 117.SIEMENS: PRODUCT PORTFOLIO
TABLE 118.THERMO FISHER: COMPANY SNAPSHOT
TABLE 119.THERMO FISHER: OPERATING SEGMENTS
TABLE 120.THERMO FISHER: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.SEGMENTATION OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET
FIGURE 02.TOP INVESTMENT POCKETS IN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2020*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENTS, 2017–2020* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2020*
FIGURE 06.LOW: BARGAINING POWER OF BUYERS
FIGURE 07.MODERATE: BARGAINING POWER OF SUPPLIERS
FIGURE 08.LOW: THREAT OF NEW ENTRANTS
FIGURE 09.MODERATE: THREAT OF SUBSTITUTION
FIGURE 10.HIGH: COMPETITIVE RIVALRY
FIGURE 11.RESTRAINTS AND DRIVERS: IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET
FIGURE 12.INFECTIOUS DISEASES PREVALENCE, 2017, (U.S.)
FIGURE 13.CHRONIC DISEASES PREVALENCE, 2017, (U.S.)
FIGURE 14.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR RADIOIMMUNOASSAY (RIA) BY COUNTRY, 2019 & 2027(%)
FIGURE 15.PREVALENCE OF DIABETES IN POPULATION (MILLIONS) AND DIABETES PREVALENCE (%)
FIGURE 16.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR IMMUNOTURBIDITY ASSAYS BY COUNTRY, 2019 & 2027(%)
FIGURE 17.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR IMMUNOPROTEIN ELECTROPHORESIS BY COUNTRY, 2019 & 2027(%)
FIGURE 18.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) BY COUNTRY, 2019 & 2027(%)
FIGURE 19.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR OTHERS BY COUNTRY, 2019 & 2027(%)
FIGURE 20.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR C-REACTIVE PROTEIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 21.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR COMPLEMENT SYSTEM PROTEIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 22.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR PRE-ALBUMIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 23.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR HAPTOGLOBIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 24.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR IMMUNOGLOBULIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 25.MULTIPLE MYELOMA, INCIDENCES AND MORTALITY (2019)
FIGURE 26.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR FREE LIGHT CHAIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 27.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR OTHERS BY COUNTRY, 2019 & 2027(%)
FIGURE 28.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR AUTOIMMUNE TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 29.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR INFECTIOUS DISEASE TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 30.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR ALLERGY TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 31.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR ENDOCRINE TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 32.ESTIMATED NUMBER OF INCIDENCES AND DEATHS FROM 2018 TO 2040, ALL CANCERS, BOTH SEXES, ALL AGES (2018)
FIGURE 33.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR ONCOLOGY TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 34.ILLICIT DRUG USE AMONG PEOPLE (IN MILLION), 2018
FIGURE 35.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR TOXICOLOGY TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 36.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR OTHERS BY COUNTRY, 2019 & 2027(%)
FIGURE 37.NUMBER AND INCIDENCE RATE PER 100,00 POPULATION OF REPORTED HEPATITIS CASES IN U.S. (2017)
FIGURE 38.ESTIMATED NUMBER OF NEW CANCER CASES VS. DEATHS AND DISTRIBUTION (%) BY TYPE (EXCLUDES NON-MELANOMA SKIN CANCER) IN EUROPE, BOTH SEXES, 2018
FIGURE 39.PERCENTAGE OF TOTAL DEATHS ATTRIBUTED TO NCDS, ALL AGES, SOUTH ASIA (2008-2030)
FIGURE 40.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 41.ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 42.ABBOTT: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 43.ABCAM: NET SALES, 2017–2019 ($MILLION)
FIGURE 44.ABCAM: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 45.BIO-RAD: NET SALES, 2017–2019 ($MILLION)
FIGURE 46.BIO-RAD: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 47.BIO-RAD: REVENUE SHARE BY REGION, 2019(%)
FIGURE 48.DANAHER: NET SALES, 2017–2019 ($MILLION)
FIGURE 49.DANAHER: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 50.DANAHER: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 51.DIASORIN: NET SALES, 2017–2019 ($MILLION)
FIGURE 52.DIASORIN: REVENUE SHARE BY REGION, 2019(%)
FIGURE 53.ENZO: NET SALES, 2017–2019 ($MILLION)
FIGURE 54.ENZO: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 55.ENZO: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 56.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 57.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 58.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 59.SIEMENS: NET SALES, 2017–2019 ($MILLION)
FIGURE 60.SIEMENS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 61.SIEMENS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 62.THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 63.THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY SEGMENTS, 2019 (%)
FIGURE 64.THERMO FISHER SCIENTIFIC. REVENUE SHARE BY REGION, 2019 (%)
FIGURE 01.SEGMENTATION OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET
FIGURE 02.TOP INVESTMENT POCKETS IN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2020*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENTS, 2017–2020* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2020*
FIGURE 06.LOW: BARGAINING POWER OF BUYERS
FIGURE 07.MODERATE: BARGAINING POWER OF SUPPLIERS
FIGURE 08.LOW: THREAT OF NEW ENTRANTS
FIGURE 09.MODERATE: THREAT OF SUBSTITUTION
FIGURE 10.HIGH: COMPETITIVE RIVALRY
FIGURE 11.RESTRAINTS AND DRIVERS: IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET
FIGURE 12.INFECTIOUS DISEASES PREVALENCE, 2017, (U.S.)
FIGURE 13.CHRONIC DISEASES PREVALENCE, 2017, (U.S.)
FIGURE 14.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR RADIOIMMUNOASSAY (RIA) BY COUNTRY, 2019 & 2027(%)
FIGURE 15.PREVALENCE OF DIABETES IN POPULATION (MILLIONS) AND DIABETES PREVALENCE (%)
FIGURE 16.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR IMMUNOTURBIDITY ASSAYS BY COUNTRY, 2019 & 2027(%)
FIGURE 17.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR IMMUNOPROTEIN ELECTROPHORESIS BY COUNTRY, 2019 & 2027(%)
FIGURE 18.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) BY COUNTRY, 2019 & 2027(%)
FIGURE 19.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR OTHERS BY COUNTRY, 2019 & 2027(%)
FIGURE 20.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR C-REACTIVE PROTEIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 21.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR COMPLEMENT SYSTEM PROTEIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 22.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR PRE-ALBUMIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 23.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR HAPTOGLOBIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 24.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR IMMUNOGLOBULIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 25.MULTIPLE MYELOMA, INCIDENCES AND MORTALITY (2019)
FIGURE 26.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR FREE LIGHT CHAIN DIAGNOSTIC TESTS BY COUNTRY, 2019 & 2027(%)
FIGURE 27.COMPARATIVE ANALYSIS OF IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR OTHERS BY COUNTRY, 2019 & 2027(%)
FIGURE 28.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR AUTOIMMUNE TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 29.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR INFECTIOUS DISEASE TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 30.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR ALLERGY TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 31.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR ENDOCRINE TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 32.ESTIMATED NUMBER OF INCIDENCES AND DEATHS FROM 2018 TO 2040, ALL CANCERS, BOTH SEXES, ALL AGES (2018)
FIGURE 33.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR ONCOLOGY TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 34.ILLICIT DRUG USE AMONG PEOPLE (IN MILLION), 2018
FIGURE 35.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR TOXICOLOGY TESTING BY COUNTRY, 2019 & 2027(%)
FIGURE 36.COMPARATIVE ANALYSIS OF IMMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, FOR OTHERS BY COUNTRY, 2019 & 2027(%)
FIGURE 37.NUMBER AND INCIDENCE RATE PER 100,00 POPULATION OF REPORTED HEPATITIS CASES IN U.S. (2017)
FIGURE 38.ESTIMATED NUMBER OF NEW CANCER CASES VS. DEATHS AND DISTRIBUTION (%) BY TYPE (EXCLUDES NON-MELANOMA SKIN CANCER) IN EUROPE, BOTH SEXES, 2018
FIGURE 39.PERCENTAGE OF TOTAL DEATHS ATTRIBUTED TO NCDS, ALL AGES, SOUTH ASIA (2008-2030)
FIGURE 40.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 41.ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 42.ABBOTT: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 43.ABCAM: NET SALES, 2017–2019 ($MILLION)
FIGURE 44.ABCAM: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 45.BIO-RAD: NET SALES, 2017–2019 ($MILLION)
FIGURE 46.BIO-RAD: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 47.BIO-RAD: REVENUE SHARE BY REGION, 2019(%)
FIGURE 48.DANAHER: NET SALES, 2017–2019 ($MILLION)
FIGURE 49.DANAHER: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 50.DANAHER: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 51.DIASORIN: NET SALES, 2017–2019 ($MILLION)
FIGURE 52.DIASORIN: REVENUE SHARE BY REGION, 2019(%)
FIGURE 53.ENZO: NET SALES, 2017–2019 ($MILLION)
FIGURE 54.ENZO: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 55.ENZO: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 56.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 57.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 58.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 59.SIEMENS: NET SALES, 2017–2019 ($MILLION)
FIGURE 60.SIEMENS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 61.SIEMENS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 62.THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 63.THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY SEGMENTS, 2019 (%)
FIGURE 64.THERMO FISHER SCIENTIFIC. REVENUE SHARE BY REGION, 2019 (%)
